Zafgen Set to Join Russell 3000® Index
BOSTON, June 25, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases, is set to …